ImmuNext, J&J in cancer deal
ImmuNext Inc. (Lebanon, N.H.) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize products that antagonize the V-region immunoglobulin-containing suppressor of T cell activation (VISTA). J&J plans to develop immunotherapies for cancer. ImmuNext will receive an upfront payment, plus milestones, which could total more than $150 million. ImmuNext is also eligible for tiered royalties. ...